Dr. Laura Dugan’s expertise in the field of Central Nervous System (CNS) diseases is widely acknowledged. She has been published extensively in all of the major peer-reviewed journals on the subject. Below is a selection of papers relating to her work in CNS and C3:
  • Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.
  • New data strongly support further development of C3 as a promising therapeutic agent for Parkinson disease.
  • Development of a fullerene-based synthetic superoxide dismutase mimetic (C3) for treatment of Central Nervous System (CNS) diseases
  • Enhancement of Apoptosis in Cerebral Endothelial Cells by Selected Inflammatory Signals
  • Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia
  • Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
  • SOD Activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study
  • A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice
  • Fullerene-based antioxidants and neurodegenerative disorders
  • IL-6 Mediated Degeneration of Forebrain GABAergic Interneurons and Cognitive Impairment in Aged Mice through Activation of Neuronal NADPH Oxidase
  • Carboxyfullerenes as neuroprotective agents
  • Mechanisms of Neuroprotection by C60 Derivatives


Click to start video
Click to view our video of Dr. Dugan, our chief researcher, and Ed Handler, our executive chairman, as they discuss C3, Fullerene Therapeutics’ novel compound.

Copyright 2019 Fullerene Therapeutics, Inc.
No part of the contents of this web site may be 
reproduced without express written permission.